Close Menu

NEW YORK – South San Francisco-based Veracyte and MaviDx said on Wednesday they have signed an agreement for MaviDx to develop ultra-high throughput genomic testing for SARS-CoV-2 on Veracyte's nCounter diagnostic platform.

As part of the collaboration, Miami-based MaviDx will develop, validate, secure regulatory approvals for, and commercialize SARS-CoV-2 and other infectious disease tests, including for influenza, on the nCounter system.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.